Cybin Inc. (CYBN.NE)
| Previous Close | 0.5000 |
| Open | 0.5100 |
| Bid | 0.4950 x 0 |
| Ask | 0.5000 x 0 |
| Day's Range | 0.4950 - 0.5100 |
| 52 Week Range | 0.3000 - 0.9800 |
| Volume | |
| Avg. Volume | 323,710 |
| Market Cap | 383.587M |
| Beta (5Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireCybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
TORONTO, May 06, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline.
Business WireCybin to Participate at the 27th Annual Milken Institute Global Conference
TORONTO, April 25, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled "Collaborating for Improved Mental Health." The Conference will
Business WireCybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
TORONTO, April 18, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that its research manuscript, entitled "Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally bioavailable and long-act
